Article
Antiviral activity of apricitabine in treatment-experienced HIV-1-infected patients with M184V who are failing combination therapy.
HIV medicine - 1 Jul 2011
Cahn P, Altclas J, Martins M, Losso M, Cassetti I, Cooper D A, Cox S
Abstract excerpt
OBJECTIVES: Apricitabine (ATC) is a novel deoxycytidine analogue nucleoside reverse transcriptase inhibitor (NRTI) with significant antiviral activity in vitro, including activity against HIV-1 with reverse transcriptase mutations that confer resistance to other NRTIs. ATC has shown promising antiviral activity and good tolerability when given as monotherapy for 10 days in treatment-naïve HIV-1-infected patients....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.